Stockreport

Preliminary Results From IMV’s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress ...

IMV Inc. - Common Shares  (IMV) 
PDF Tumor regressions and partial responses observed in subjects with ovarian, non-small cell lung and bladder cancerTreatment well-tolerated, with no related Grade 3-4 or i [Read more]